CureVac NV (FRA:5CV) NonCurrent Deferred Liabilities : €40.04 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

CureVac NV's non-current deferred liabilities for the quarter that ended in Mar. 2024 was €40.04 Mil.

CureVac NV NonCurrent Deferred Liabilities Historical Data

The historical data trend for CureVac NV's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV NonCurrent Deferred Liabilities Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

67.66

500.06

86.35

72.55

48.10

CureVac NV Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															72.55	58.86	53.02	48.10	40.04

CureVac NV NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of CureVac NV's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (FRA:5CV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (FRA:5CV) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

CureVac NV (FRA:5CV) Headlines

No Headlines